ZA201004357B - Prodrugs of artemisinin - Google Patents

Prodrugs of artemisinin

Info

Publication number
ZA201004357B
ZA201004357B ZA2010/04357A ZA201004357A ZA201004357B ZA 201004357 B ZA201004357 B ZA 201004357B ZA 2010/04357 A ZA2010/04357 A ZA 2010/04357A ZA 201004357 A ZA201004357 A ZA 201004357A ZA 201004357 B ZA201004357 B ZA 201004357B
Authority
ZA
South Africa
Prior art keywords
artemisinin
prodrugs
Prior art date
Application number
ZA2010/04357A
Inventor
David Dago N'da
Jaco Cornelius Breytenbach
Michael L Ashton
Original Assignee
North-West Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North-West Univ filed Critical North-West Univ
Publication of ZA201004357B publication Critical patent/ZA201004357B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2010/04357A 2008-09-19 2010-06-21 Prodrugs of artemisinin ZA201004357B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA200808051 2008-09-19
PCT/IB2009/053940 WO2010032165A2 (en) 2008-09-19 2009-09-09 Prodrugs of artemisinin

Publications (1)

Publication Number Publication Date
ZA201004357B true ZA201004357B (en) 2011-06-29

Family

ID=41786289

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/04357A ZA201004357B (en) 2008-09-19 2010-06-21 Prodrugs of artemisinin

Country Status (2)

Country Link
WO (1) WO2010032165A2 (en)
ZA (1) ZA201004357B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11365202B2 (en) * 2018-04-16 2022-06-21 Council Of Scientific And Industrial Research Antimalarial compounds, process for preparation and their use for drug resistant malaria
CN110590803B (en) * 2019-08-28 2022-03-04 西南大学 Dihydroartemisinin carbonyl phenol-containing conjugate, reduction product thereof, synthetic method and application
CN111548355B (en) * 2020-04-29 2021-08-03 宁夏大学 Artemisia apiacea sulfone-piperazine-furanone derivative and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974354A1 (en) * 1998-07-14 2000-01-26 The Hong Kong University of Science & Technology Artemisinin derivatives
CN1105722C (en) * 1999-11-12 2003-04-16 中国科学院上海药物研究所 Arteannuin derivant containing azacyclic radical and preparation process thereof
AU2006323040A1 (en) * 2005-12-08 2007-06-14 Johns Hopkins University Trioxane dimers having high anticancer and long-lasting antimalarial activities
BRPI0700836A (en) * 2007-03-20 2008-11-04 Fundacao Oswaldo Cruz substituted quinoline derivatives, process for preparing these derivatives, pharmaceutical composition containing said derivatives, use of such derivatives in the treatment or prevention of malaria or other parasitic diseases and therapeutic method

Also Published As

Publication number Publication date
WO2010032165A3 (en) 2010-11-18
WO2010032165A2 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
HRP20140223T1 (en) Dolutegravir prodrugs
GB2454029B (en) Trampoline
EP2445343A4 (en) Prodrugs of nh-acidic compounds
EP2304603A4 (en) Structured coauthoring
EP2339918A4 (en) Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide
EP2443235A4 (en) ß-GLUCOSIDASE VARIANTS
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
IL218683A0 (en) Prodrugs of guanfacine
EP2438246A4 (en) Aspects of construction
PL2133419T3 (en) Uses of cyanophycin beta-dipeptides
IL219029A0 (en) Pyrazolopyrimidine derivatives
GB0913485D0 (en) Surface modification
EP2350385A4 (en) Forming section
HK1168107A1 (en) Triptolide prodrugs
ZA201008076B (en) Calibration of dtonators
IL213673A0 (en) Spiroindolinone derivative prodrugs
HK1160925A1 (en) Use of athepsin
ZA201008911B (en) Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs
ZA201004357B (en) Prodrugs of artemisinin
EP2358693A4 (en) Preparation of docetaxel
GB0813347D0 (en) A set of parts
EP2331490A4 (en) Preparation of dibutoxymethane
GB0816419D0 (en) Production of hydroelecticity
GB0905127D0 (en) Novel prodrugs
GB0900963D0 (en) Playing card-chess set